Chiesi USA’s Kengreal Analyzed in CAMEO Registry for Use and Transition to Oral P2Y12 Inhibitors in Routine Clinical Practice

June 1, 2022—Chiesi USA, the United States affiliate of Italy-based Chiesi Farmaceutici, announced the publication of the first full analysis from its CAMEO (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes) registry that evaluated Kengreal (cangrelor) use and transition to oral P2Y12 inhibitors in routine clinical practice.

The CAMEO registry is a multicenter, retrospective, observational study examining platelet inhibition strategies during the early management of myocardial infarction (MI) patients undergoing percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery.

Kengreal for injection is a P2Y12 platelet inhibitor indicated as an adjunct to PCI to reduce the risk of periprocedural MI, repeat coronary revascularization, and stent thrombosis in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

These results from the ongoing registry were published by Jennifer A. Rymer, MD, et al online in the Journal of the American Heart Association. The company noted that select findings from this first analysis were also presented at ACC.22, the American College of Cardiology’s 71st annual scientific session held April 2-4 in Washington, DC.

Dr. Rymer, who is an interventional cardiologist at Duke University Medical Center in Durham, North Carolina, commented in the company’s press release, “CAMEO has captured invaluable patient data that reflects contemporary P2Y12 inhibitor use from a variety of health centers across the United States. This registry will be helpful in evaluating how, when, and in what patients Kengreal is currently being utilized in clinical practice. We need to improve processes and systems of care to ensure patients receive the full benefit of Kengreal.”

According to the company, the CAMEO registry aims to collect information on 3,000 patients with non-ST segment elevation MI or ST segment elevation MI treated with Kengreal or an oral P2Y12 inhibitor. The patients were enrolled at 12 sites, which were selected to represent a wide geographic distribution and a variety of types of university-based and non-university-based hospitals.

This first analysis included data from approximately 800 patients at nine study sites. Interhospital use of Kengreal in acute MI varied, and the utilization also differed among patient presentations. The analysis was able to characterize Kengreal dosing and patterns of transition to an oral P2Y12 inhibitor in routine practice.

The registry has achieved approximately 80% enrollment to date, and subsequent analyses will provide insights on uptake and utilization of cangrelor in routine clinical practice among PCI centers in the United States and observations into real-world outcomes in MI patients, advised Chiesi USA.